Literature DB >> 29903895

Bigger Is Not Always Better: Tumor Size and Prognosis in Advanced Melanoma.

Allison Betof Warner1, Michael A Postow2,3.   

Abstract

Tumor burden is a key consideration for the treatment of solid malignancies. Large baseline tumor size (an assessment of volume of disease in target lesions prior to treatment), elevated lactate dehydrogenase (LDH), and site of disease are prognostic of poor overall survival (OS) for patients with advanced melanoma treated with pembrolizumab. Clin Cancer Res; 24(20); 4915-7. ©2018 AACR See related article by Joseph et al., p. 4960. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29903895     DOI： 10.1158/1078-0432.CCR-18-1311

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  6 in total

1.  Prognostic Clinical and Radiographic Biomarkers for BRAF-Targeted Therapy in Advanced Melanoma.

Authors:  Kaustav P Shah; Haocan Song; Fei Ye; Douglas B Johnson
Journal:  Oncologist       Date:  2020-11-04       Impact factor: 5.837

Review 2.  Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies.

Authors:  Yumi Kambayashi; Taku Fujimura; Takanori Hidaka; Setsuya Aiba
Journal:  Front Med (Lausanne)       Date:  2019-07-31

3.  Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.

Authors:  E E A P Mulder; K de Joode; S Litière; A J Ten Tije; K P M Suijkerbuijk; M J Boers-Sonderen; G A P Hospers; J W B de Groot; A J M van den Eertwegh; M J B Aarts; D Piersma; R S van Rijn; E Kapiteijn; G Vreugdenhil; F W P J van den Berkmortel; E Oomen-de Hoop; M G Franken; B Ryll; P Rutkowski; S Sleijfer; J B A G Haanen; A A M van der Veldt
Journal:  BMC Cancer       Date:  2021-03-25       Impact factor: 4.430

Review 4.  Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.

Authors:  Kimberly Loo; James W Smithy; Michael A Postow; Allison Betof Warner
Journal:  Front Immunol       Date:  2022-01-11       Impact factor: 7.561

5.  The long-term impact of tumor burden in pT3N0M0 esophageal squamous cell carcinoma: A propensity score-matched analysis.

Authors:  Tingting Li; Xiaobin Fu; Lihua Xiao; Liyu Su; Yaqing Dai; Qiwei Yao; Jiancheng Li
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

6.  Lower risk of severe checkpoint inhibitor toxicity in more advanced disease.

Authors:  Rik J Verheijden; Anne M May; Christian U Blank; Astrid A M van der Veldt; Marye J Boers-Sonderen; Maureen J B Aarts; Franchette W P J van den Berkmortel; Alfonsus J M van den Eertwegh; Jan Willem B de Groot; Jacobus J M van der Hoeven; Geke A P Hospers; Djura Piersma; Rozemarijn S van Rijn; Albert J Ten Tije; Gerard Vreugdenhil; Michiel C T van Zeijl; Michel W J M Wouters; John B A G Haanen; Ellen Kapiteijn; Karijn P M Suijkerbuijk
Journal:  ESMO Open       Date:  2020-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.